Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets remain buoyant
Fri, 12 Jul 01:30 pm

Backed on strong buying in index heavy-weights Indian share markets continued to trade higher in the post-noon trading session. Majority of the sectoral indices are trading mixed with consumer durables, realty and auto stocks being the biggest losers. However, IT, capital goods and pharma stocks are trading in the green.

BSE-Sensex is up 135 points and NSE-Nifty is trading 26 points up. However, BSE Mid Cap is trading down 0.3% and BSE Small Cap index is trading down by 0.2%. The rupee is trading at 59.9 to the US dollar.

Majority of the mining stocks are trading in the red with Metals and Minerals Trading Corporation of India Ltd. (MMTC) and Manganese Ore of India Ltd (MOIL) being the major losers. However, National Mineral Development Corporation (NMDC) and Hindustan Zinc are trading positive. As per a leading financial daily, MOIL has won prospecting licenses in 11 blocks situated over an area of 597.4 hectares in the Nagpur and Bhandara districts of Maharashtra. The company is already operating six mines in Maharashtra and four mines in Madhya Pradesh. The award of new licenses will increase its total leasehold area by 33.2% to 2396 hectares. MOIL has already earmarked an amount of Rs 2.5 bn for conducting geophysical studies, exploratory drilling etc. in the new blocks allotted. By 2020-21, the company has plans of achieving a production target of 2.2 m tonnes from the existing mines.

Pharma stocks are trading mixed with Elder Pharma and Strides Acrolabs among leading gainers while JB Chemicals and Orchid Chemicals are witnessing maximum selling pressures. Sun Pharmaceutical recently announced that the USFDA (United States Food and Drug Administration) has given final approval to its subsidiary Caraco for an Abbreviated New Drug Applications (ANDA) for generic version of Prandin tablets. The drug is generically known as repaglinide. Sun Pharma was first to file the drug and thus is eligible for 180-days exclusivity. The said drug is therapeutically equivalent to Novo Nordisk's Prandin brand. The annual sales of this drug are $ 200 m and are used for patients suffering from Type II diabetes. Sun Pharma stock was trading down by 0.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets remain buoyant". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.